Out of stock quickly.France ordered only 200,000 doses for 700,000 annual births. All parents of babies then found themselves in the same situation, going from pharmacy to pharmacy to get a dose that would protect their child (often in vain).
Eligibility criteria
This year, Sanofi, the laboratory that develops Beyfortus, produced 600,000 doses to avoid shortages. In mainland France, all children born after January 1, 2024 are entitled to it. The rule is identical in Guyana, Martinique, Saint-Martin and Saint-Barthélémy. This date is set for February 1 for Reunion and Guadeloupe and March 15 for Mayotte.
According to Vidal, a reference book for health products, Beyfortus “is indicated for infants at high risk of RSV infection born at gestational age of 35 weeks or less and less than 6 months at the beginning of the seasonal RSV epidemic; under 2 years who required treatment for bronchopulmonary dysplasia in the last 6 months; under 2 years of age suffering from congenital heart diseases with hemodynamic impact.